The effect of interferon-β on mouse neural progenitor cell survival and differentiation

Biochemical and Biophysical Research Communications

Volumn 388, Issue 2, 2009, Pages 181-186

  Hirsch, Marek ^a   Knight, Julia ^a   Tobita, Mari ^a   Soltys, John ^a   Panitch, Hillel ^a   Mao Draayer, Yang ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

IFN receptor; Interferon ; Mouse neural progenitor cells; Multiple sclerosis; Neuroprotection; STAT signaling

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON; BETA INTERFERON RECEPTOR; CASPASE 12; CASPASE 2; CASPASE RECRUITMENT DOMAIN PROTEIN 4; INTERLEUKIN 1BETA CONVERTING ENZYME; STAT1 PROTEIN; STAT2 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IN VITRO STUDY; MOUSE; NEURAL STEM CELL; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; GENE EXPRESSION REGULATION; INTERFERON-BETA; MICE; NEUROGENESIS; NEURONS; NEUROPROTECTIVE AGENTS; RECEPTOR, INTERFERON ALPHA-BETA; STEM CELLS;

EID: 69249202262     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.07.073     Document Type: Article

References (39)

1. Stangel M. Neuroprotection and neuroregeneration in multiple sclerosis. J. Neurol. 255 6 (2008) 77-81
2. Lucchinetti C., Nruck W., Parisi J., Scheithaue Br., Rodriguez M., and Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 (2000) 707-717
3. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3 (2002) 291-301
4. De Jager P.L., and Hafler D.A. New therapeutic approaches for multiple sclerosis. Annu. Rev. Med. 58 (2007) 417-432
5. Galetta S.L., Markowitz C., and Lee A.G. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch. Intern. Med. 62 19 (2002) 12161-12169
6. Panitch H., Goodin D.S., Francis G., Chang P., Coyle P.K., O'Connor P., Monaghan E., Li D., Weinshenker B., and EVIDENCE Study Group. Evidence of interferon dose-response: Europian North American Comparative Efficacy; University of British Columbia MS/MRI Research Group Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 59 (2002) 1496-1506
7. Schwid S.R., Thorpe J., Sharief M., Sandberg-Wollheim M., Rammohan K., Wendt J., Panitch H., Goodin D., David L.D., Chang P., Francis G., and for the EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE study. Arch. Neurol. 62 (2005) 785-792
8. Rudick R.A., Fisher E., Lee J.C., Simon J., Jacob L., and Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 53 (1999) 1698-1704
9. Narayanan S., DeStefano N., Francis G.S., Arnaoutelis R., Caramanos Z., Collins D.L., Pelletier D., Arnason B.G.W., Antel J.P., and Arnold D.L. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J. Neurol. 248 (2001) 979-986
10. Pluchino S., and Martino G. The therapeutic plasticity of neural stem/precursor cells in multiple sclerosis. J. Neurol. Sci. 265 1-2 (2008) 105-110
11. Oritani K., Kincade P.W., Zhang C., Tomiyama, and Matsuzawa Y. Type I interferons and limit in: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev. 12 (2001) 337-348
12. Deleyrolle L., Marchal-Victorian S., Dromard C., Fritz V., Saunier M., Sabourin J.-C., Tran Van Ba C., Privat A., and Hugnot J.-P. Exogenous and fibroblast growth factor 2/epidermal growth factor-regulated endogenous cytokines regulate neural precursor cell growth and differentiation. Stem Cells 24 (2005) 748-762
13. Gigli G., Caielli S., Cutuli D., and Falcone M. Innate immunity modulates autoimmunity: type 1 interferon-β treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dentritice cell maturation. Immunology 122 3 (2007) 409-417
14. Chofflon M. Mechanisms of action for treatments in multiple sclerosis: dose a heterogeneous disease demand a multi-targeted therapeutic approach?. Bio Drugs 19 (2005) 299-308
15. Ihle J.N. Cytokine receptor signaling. Nature 337 (1995) 591-594
16. Schindler S., and Darnell J.J.E. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64 29 (1995) 621-651
17. Darnell Jr., Kerr I.M., and Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signal proteins. Science 264 (1994) 1415-1421
18. Goodbourn S., Didcock L., and Randall R.E. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81 (2000) 2341-2364
19. Levy D., Kessler D., Pine R., Reich N., and Darnell Jr. J. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative control. Genes Dev. 2 (1988) 383-393
20. Memet S. NFkB functions in the nervous system: from development to disease. Biochem. Pharmacol. 72 (2006) 180-1195
21. Franchi L., Eigenbrod T., Munoz-Planillo R., and Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 10 3 (2009) 241-247
22. Kufer T.A., Kremmer E., Adam A.C., Philpott D.J., and Sansonetti P.J. The pattern recognition molecule Nod1 is localized at the plasma membrane at sites of bacterial interaction. Cell Microbiol. 10 (2008) 477-486
23. Fritz, et al. Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 26 (2007) 445-459
24. Inohara N., and Nunez G. The NOD: a signaling module that regulates apoptosis and host defense against pathogens. Oncogene 20 (2001) 6473-6481
25. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 97 (2006) 439-447
26. Wajant H. TRAIL and NF kappaB signaling-a complex relationship. Vitamin Horm. 67 (2004) 101-132
27. Hilliard B. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol. 166 (2001) 1314-1319
28. Wang Y., et al. Protective effects of glial cell-line derived neurotrophic factor in ischemic brain injury. Ann. N.Y. Acad. Sci. 962 (2002) 423-438
29. Beck K.D., Valverde J., and Alexi T. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373 (1995) 339-341
30. Henderson C.E., Phillips H.S., and Pollock R.A. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266 (1994) 1062-1064
31. Trok K., Hoffer B., and Olson L. Glial cell line-derived neurotrophic factor enhances survival and growth of prenatal and postnatal spinal cord transplants. Neuroscience 71 (1996) 231-241
32. Yan Q., Matheson C., and Lopez O.T. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature 373 (1995) 341-344
33. Aarnisalo A.A., Pirvola U., and Liang X.Q. Apoptosis in auditory brain-stem neurons after a severe noise trauma of the organ of Corti: intracochlear GDNF treatment reduces the number of apoptotic cells. ORL J. Otorhinolaryngol. Relat. Spec. 62 (2000) 330-334
34. McAlhany R.E., West J.R., and Miranda R.C. Glial-derived neurotrophic factor (GDNF) prevents ethanol-induced apoptosis and JUN kinase phosphorylation. Brain Res. Dev. Brain Res. 119 (2000) 209-216
35. Ferrari G., Minozzi M.C., Zanellato A.M., and Silvestrini B. GM1, like IGF-I and GDNF, prevents neuronal apoptosis. Ann. N.Y. Acad. Sci. 845 (1998) 408
36. Clarkson E.D., Zawada W.M., and Freed C.R. GDNF reduces apoptosis in dopaminergic neurons in vitro. Neuroreport 7 (1995) 145-149
37. Niino M., Fukazawa T., Kikuchi S., and Sasaki H. Therapeutic potential of vitamin D for multiple sclerosis. Curr. Med. Chem. 15 5 (2008) 499-505
38. Hoffer B.J., Hoffman A., and Bowenkamp K. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182 (1994) 107-111
39. Bowenkamp K.E., Hoffman A.F., and Gerhardt G.A. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355 (1995) 479-489